It is the first Immuno-STAT to be investigated in HNSCC, and is designed to bind, expand, and activate HPV16-specific CD8+ T cells for the treatment of HPV16+ cancers [47]. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.